… the FDA has given clearance to ZEISS Medical’s INTRABEAM … efficient treatment workflow. READ MORE: Argatroban Plus Dual Antiplatelet Treatment Proves … several large-scale clinical trials investigating IORT in … phase 3 INTRAGO-II trial of glioblastoma (data …

… a recently published randomized controlled trial, treatment with argatroban plus dual antiplatelet therapy … 2 treatment groups, 20.4% (n = 10) of patients on argatroban plus …

… In this randomized controlled trial, among ischemic stroke … argatroban, an anticoagulant, or eptifibatide, an antiplatelet. However, other trials … which favored the treatment group showing greater benefit … the most from enhanced medical reperfusion, could have …

… treatment with intravenous argatroban, an anticoagulant agent, or eptifibatide (Integrillin; Millennium Pharmaceuticals … “Without negative trials, we would … neurosurgery, McGovern Medical School at … clotting drugs to stroke care ineffective, clinical trial …

… of Emergency Medicine by Adeoye et al. The standard treatment of acute … conducted a clinical trial to compare the effects of argatroban, eptifibatide, and … (8%). They concluded adjunctive treatment with argatroban or eptifibatide did not improve …

… England Journal of Medicine revealed that the addition of argatroban, an anticoagulant … standard treatment for acute ischemic stroke, this trial demonstrates that adding argatroban or … 9, pp. 810–820). Massachusetts Medical Society. https://doi …

… Medicine) in the US have found that adding anti-clotting stroke drugs … trial evaluated the efficacy of argatroban and eptifibatide alongside routine intravenous thrombolysis treatment. Argatroban … The trial was spearheaded by WashU Medicine department …

… clots, doctors at 57 … medicine, including potential new anti-coagulant treatments. “Without negative trials … drugs seemed like a promising idea, especially as there are FDA-approved medications … trial, patients were randomly assigned to receive either argatroban …

… clots, doctors at 57 … medicine, including potential new anti-coagulant treatments. “Without negative trials … drugs seemed like a promising idea, especially as there are FDA-approved medications … trial, patients were randomly assigned to receive either argatroban …

… clots, doctors at 57 … medicine, including potential new anti-coagulant treatments. “Without negative trials … drugs seemed like a promising idea, especially as there are FDA-approved medications … trial, patients were randomly assigned to receive either argatroban …